Answers are grounded in this paper and cite their sources.
This review explores treatment strategies for hidradenitis suppurativa, highlighting antibiotics and biologics.
Purpose: This review provides a comprehensive overview of the pharmacological management of Hidradenitis suppurativa (HS), including topical, systemic, and biological agents.Current Concepts: HS is a chronic, recurrent inflammatory skin disease characterized by painful nodules, abscesses, purulent discharge, and sinus tract formation, predominantly in intertriginous areas. It significantly impairs quality of life due to persistent pain and psychological distress. While lifestyle modifications and surgical interventions are important components of management, pharmacological therapy remains central to controlling disease activity and preventing progression. Antibiotics, including tetracyclines, clindamycin, and rifampicin combinations, serve as first-line agents for early or mild-to-moderate disease. Hormonal therapies, such as spironolactone and oral contraceptives, have demonstrated efficacy in selected female patients. Retinoids, including isotretinoin and acitretin, may be beneficial, particularly in cases with coexistent acne, although relapse is common after discontinuation. Biologics have emerged as key treatments for moderate-to-severe HS. Adalimumab, the only tumor necrosis factor-α inhibitor currently approved for HS, has shown significant efficacy. Interleukin-17 inhibitors, such as secukinumab and bimekizumab, have also demonstrated promising results in large phase 3 trials.Discussion and Conclusion: Effective HS management requires a personalized approach tailored to disease severity. While antibiotics remain central in the early stages of inflammation, biologics have become a cornerstone of treatment in patients with recurrent flare-ups and severe disease. The ongoing development of targeted therapies and advances in understanding the pathogenesis of HS are expected to further improve clinical outcomes, providing greater hope for enhanced patient satisfaction and long-term disease control.
No takes yet. Share an insight, caveat, or question.
Yu Sung Choi (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: